Search Results - "Vera Badillo, Francisco E."

Canadian consensus on TRK‐inhibitor therapy for NTRK fusion‐positive sarcoma by Simmons, Christine, Deyell, Rebecca J., MacNeill, Andrea J., Vera‐Badillo, Francisco E., Smrke, Alannah, Abdul Razak, Albiruni R., Banerji, Shantanu, McLeod, Deanna, Noujaim, Jonathan

“…Malignant sarcomas are rare accounting for <1% of all adult solid malignancies and approximately 11% to 13% of all pediatric malignancies. TRK‐inhibitors have…”
Get full text

Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis by TEMPLETON, Arnoud J, MCNAMARA, Mairéad G, TANNOCK, Ian F, AMIR, Eitan, SERUGA, Boštjan, VERA-BADILLO, Francisco E, ANEJA, Priya, OCANA, Alberto, LEIBOWITZ-AMIT, Raya, SONPAVDE, Guru, KNOX, Jennifer J, TRAN, Ben

“…Inflammation may play an important role in cancer progression, and a high neutrophil-to-lymphocyte ratio (NLR) has been reported to be a poor prognostic…”
Get full text

Can Oncogenic Driver Alterations be Responsible for the Lack of Immunotherapy Efficacy in First-line Advanced Urothelial Carcinoma? by Kartolo, Adi, Robinson, Andrew, Vera Badillo, Francisco E.

“…Urothelial carcinoma (UC) harbors many oncogenic alterations and the limited efficacy of first-line immunotherapy in this setting suggests that oncogenic…”
Get full text

Prognostic Role of Platelet to Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis by TEMPLETON, Arnoud J, ACE, Olga, MCNAMARA, Mairéad G, AL-MUBARAK, Mustafa, VERA-BADILLO, Francisco E, HERMANNS, Thomas, SERUGA, Boštjan, OCANA, Alberto, TANNOCK, Ian F, AMIR, Eitan

“…Inflammation influences cancer development and progression. An elevated platelet to lymphocyte ratio (PLR), a marker of inflammation, has been linked to poor…”
Get full text

Management of Metastatic Hormone-Sensitive Prostate Cancer: Is Docetaxel Needed? by Kartolo, Adi, Tannock, Ian F., Vera Badillo, Francisco E.

Get full text

Systemic Therapy for Non–clear Cell Renal Cell Carcinomas: A Systematic Review and Meta-analysis by Vera-Badillo, Francisco E, Templeton, Arnoud J, Duran, Ignacio, Ocana, Alberto, de Gouveia, Paulo, Aneja, Priya, Knox, Jennifer J, Tannock, Ian F, Escudier, Bernard, Amir, Eitan

“…Abstract Context Clinical data supporting the use of targeted agents for the treatment of metastatic renal cell carcinoma (RCC) are based predominantly on…”
Get full text

Simple prognostic score for metastatic castration‐resistant prostate cancer with incorporation of neutrophil‐to‐lymphocyte ratio by Templeton, Arnoud J., Pezaro, Carmel, Omlin, Aurelius, McNamara, Mairéad G., Leibowitz‐Amit, Raya, Vera‐Badillo, Francisco E., Attard, Gerhardt, de Bono, Johann S., Tannock, Ian F., Amir, Eitan

“…BACKGROUND The neutrophil‐to‐lymphocyte ratio (NLR), a marker of inflammation, has been reported to be a poor prognostic indicator in prostate cancer. Here we…”
Get full text

Metastatic prostate cancer gets into the biomarker era by Badillo, Francisco E. Vera

Get full text

Epidermal growth factor receptor overexpression and outcomes in early breast cancer: A systematic review and a meta-analysis by Gonzalez-Conchas, Galileo A., Rodriguez-Romo, Laura, Hernandez-Barajas, David, Gonzalez-Guerrero, Juan F., Rodriguez-Fernandez, Ivan A., Verdines-Perez, Adrian, Templeton, Arnoud J., Ocana, Alberto, Seruga, Bostjan, Tannock, Ian F., Amir, Eitan, Vera-Badillo, Francisco E.

“…•EGFR overexpression is associated with reduced OS in women with early breast cancer.•EGFR overexpression is associated with reduced DFS in women with early…”
Get full text

NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer by Klümper, Niklas, Tran, Ngoc Khanh, Zschäbitz, Stefanie, Hahn, Oliver, Büttner, Thomas, Roghmann, Florian, Bolenz, Christian, Zengerling, Friedemann, Schwab, Constantin, Nagy, Dora, Toma, Marieta, Kristiansen, Glen, Heers, Hendrik, Ivanyi, Philipp, Niegisch, Günter, Grunewald, Camilla Marisa, Darr, Christopher, Farid, Arian, Schlack, Katrin, Abbas, Mahmoud, Aydogdu, Can, Casuscelli, Jozefina, Mokry, Theresa, Mayr, Michael, Niedersüß-Beke, Dora, Rausch, Steffen, Dietrich, Dimo, Saal, Jonas, Ellinger, Jörg, Ritter, Manuel, Alajati, Abdullah, Kuppe, Christoph, Meeks, Joshua, Vera Badillo, Francisco E, Nakauma-González, J Alberto, Boormans, Joost, Junker, Kerstin, Hartmann, Arndt, Grünwald, Viktor, Hölzel, Michael, Eckstein, Markus

“…The anti-NECTIN4 antibody-drug conjugate enfortumab vedotin (EV) is approved for patients with metastatic urothelial cancer (mUC). However, durable benefit is…”
Get full text

Complete response and survival outcomes in patients with advanced cancer on immune checkpoint inhibitors by Kartolo, Adi, Yeung, Cynthia, Hopman, Wilma, Fung, Andrea S, Baetz, Tara, Vera Badillo, Francisco E

“…To evaluate overall survival in advanced cancer patients who achieved complete response (CR) with immune checkpoint inhibitor (ICI) therapy. This retrospective…”
Get full text

Prognostic role of Ki-67 score in localized prostate cancer: A systematic review and meta-analysis by Berlin, Alejandro, Castro-Mesta, Julio F., Rodriguez-Romo, Laura, Hernandez-Barajas, David, González-Guerrero, Juan F., Rodríguez-Fernández, Iván A., González-Conchas, Galileo, Verdines-Perez, Adrian, Vera-Badillo, Francisco E.

“…Ki-67 for quantifying tumor proliferation is widely used. In localized prostate cancer (PCa), despite a suggested predictive role of Ki-67 for outcomes after…”
Get full text

Perioperative chemotherapy for urothelial carcinoma of the upper urinary tract: A systematic review and meta-analysis by Gregg, Richard W., Vera-Badillo, Francisco E., Booth, Christopher M., Mahmud, Aamer, Brundage, Michael, Leveridge, Michael J., Hanna, Timothy P.

“…Upper tract urothelial carcinomas are rare malignancies with differences in anatomy and biology requiring therapeutic strategies that differ from bladder…”
Get full text

Interaction between Hormonal Receptor Status, Age and Survival in Patients with BRCA1/2 Germline Mutations: A Systematic Review and Meta-Regression by Templeton, Arnoud J, Gonzalez, Laura Diez, Vera-Badillo, Francisco E, Tibau, Ariadna, Goldstein, Robyn, Šeruga, Boštjan, Srikanthan, Amirrtha, Pandiella, Atanasio, Amir, Eitan, Ocana, Alberto

“…Germline mutations in the BRCA1 and BRCA2 genes are the most frequent known hereditary causes of familial breast cancer. Little is known about the interaction…”
Get full text

Discussion of Treatment Options for Metastatic Hormone Sensitive Prostate Cancer Patients by Sigurdson, Samantha S, Vera-Badillo, Francisco E, de Moraes, Fabio Ynoe

Get full text

Management of Favorable-risk Advanced Renal Cell Carcinoma: Is Dual Therapy the Answer? by Kartolo, Adi, Procopio, Giuseppe, Vera-Badillo, Francisco E.

Get full text

Changes to Primary End Points in Randomized Clinical Trials on Immune Checkpoint Inhibitors in Urothelial, Renal Cell, and Lung Cancers: A Systematic Review by Richters, Anke, Yildirim, Hilin, Booth, Christopher M, Vera Badillo, Francisco E, Kiemeney, Lambertus A L M, Aben, Katja K H

Get more information

Study of testosterone-guided androgen deprivation therapy in management of prostate cancer by Niraula, Saroj, Templeton, Arnoud J., Vera-Badillo, Francisco E., Joshua, Anthony M., Sridhar, Srikala S., Cheung, Peter W., Yip, Paul M., Dodd, Anna, Nugent, Zoann, Tannock, Ian F.

“…BACKGROUND Androgen deprivation therapy (ADT) with luteinizing hormone releasing hormone (LHRH) agonists is an effective initial therapy for men with advanced…”
Get full text

Fibroblast Growth Factor Receptor 3 Mutation as a Prognostic Indicator in Patients with Urothelial Carcinoma: A Systematic Review and Meta-analysis by Khalid, Sidra, Basulaiman, Bassam Mohammed, Emack, Jeffrey, Booth, Christopher M., Duran, Ignacio, Robinson, Andrew G., Berman, David, Smoragiewicz, Martin, Amir, Eitan, Vera-Badillo, Francisco E.

“…Fibroblast growth factor receptor 3 (FGFR3) mutations have been implicated in urothelial tumorigenesis. FGFR3 inhibitors are being explored in clinical trials…”
Get full text

Retreatment of men with metastatic castrate-resistant prostate cancer with abiraterone by Leibowitz-Amit, Raya, Alimohamed, Nimira, Vera-Badillo, Francisco E., Seah, Jo-An, Templeton, Arnoud J., Knox, Jennifer J., Tannock, Ian F., Sridhar, Srikala S., Joshua, Anthony M.

“…BACKGROUND Abiraterone acetate (AA), oral CYP17 inhibitor, is an active agent in the treatment of metastatic castrate‐resistant prostate cancer (mCRPC)…”
Get full text